Probiotic lactobacillus and bifidobacterium strains counteract adherent-invasive escherichia coli (AIEC) virulence and hamper il-23/th17 axis in ulcerative colitis, but not in crohn’s disease

52Citations
Citations of this article
82Readers
Mendeley users who have this article in their library.

Abstract

Hypersecretion of proinflammatory cytokines and dysregulated activation of the IL-23/Th17 axis in response to intestinal microbiota dysbiosis are key factors in the pathogenesis of inflammatory bowel diseases (IBD). In this work, we studied how Lactobacillus and Bifidobacterium strains affect AIEC-LF82 virulence mechanisms and the consequent inflammatory response linked to the CCR6–CCL20 and IL-23/Th17 axes in Crohn’s disease (CD) and ulcerative colitis (UC) patients. All Lactobacillus and Bifidobacterium strains significantly reduced the LF82 adhesion and persistence within HT29 intestinal epithelial cells, inhibiting IL-8 secretion while not affecting the CCR6–CCL20 axis. Moreover, they significantly reduced LF82 survival within macrophages and dendritic cells, reducing the secretion of polarizing cytokines related to the IL-23/Th17 axis, both in healthy donors (HD) and UC patients. In CD patients, however, only B. breve Bbr8 strain was able to slightly reduce the LF82 persistence within dendritic cells, thus hampering the IL-23/Th17 axis. In addition, probiotic strains were able to modulate the AIEC-induced inflammation in HD, reducing TNF-α and increasing IL-10 secretion by macrophages, but failed to do so in IBD patients. Interestingly, the probiotic strains studied in this work were all able to interfere with the IL-23/Th17 axis in UC patients, but not in CD patients. The different interaction mechanisms of probiotic strains with innate immune cells from UC and CD patients compared to HD suggest that testing on CD-derived immune cells may be pivotal for the identification of novel probiotic strains that could be effective also for CD patients.

References Powered by Scopus

Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases

3757Citations
N/AReaders
Get full text

Infliximab, azathioprine, or combination therapy for Crohn's disease

2823Citations
N/AReaders
Get full text

A genome-wide association study identifies IL23R as an inflammatory bowel disease gene

2639Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The Diversity of Escherichia coli Pathotypes and Vaccination Strategies against This Versatile Bacterial Pathogen

91Citations
N/AReaders
Get full text

Pathobionts in Inflammatory Bowel Disease: Origins, Underlying Mechanisms, and Implications for Clinical Care

59Citations
N/AReaders
Get full text

A novel combination therapy using rosuvastatin and lactobacillus combats dextran sodium sulfate-induced colitis in high-fat diet-fed rats by targeting the TXNIP/NLRP3 interaction and influencing gut microbiome composition

48Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Leccese, G., Bibi, A., Mazza, S., Facciotti, F., Caprioli, F., Landini, P., & Paroni, M. (2020). Probiotic lactobacillus and bifidobacterium strains counteract adherent-invasive escherichia coli (AIEC) virulence and hamper il-23/th17 axis in ulcerative colitis, but not in crohn’s disease. Cells, 9(8), 1–20. https://doi.org/10.3390/cells9081824

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 10

50%

Researcher 6

30%

Professor / Associate Prof. 4

20%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 9

39%

Agricultural and Biological Sciences 6

26%

Nursing and Health Professions 4

17%

Immunology and Microbiology 4

17%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
Social Media
Shares, Likes & Comments: 18

Save time finding and organizing research with Mendeley

Sign up for free